Leaders In The Development of Next Generation Psychoactive Pharmaceuticals
PsyBio retains the global exclusive rights to a platform technology enabling highly efficient drug discovery, development, and production for pharmaceutical candidates through synthetic biology and metabolic engineering.
Why PsyBio Will be the Leader in the Psychedelic Drug Discovery Industry
Progress for Top
40 Individual
Molecules
Current Pipeline:
88 Individual
Molecules
Fully Capitalized:
Triple Subscribed Institutional
Round
IND and Clinical Trials: Pre-IND Submission in 2021 & Clinical Trials in 2022
Intellectual Property:
Blanket Submissions in Combinatorial Bacterial and Hybrid Synthesis
Psybio Media
Videos
Learn More About Psybio's Progress, The People Behind It, And It's Evolution To Addressing Mental Health.
Podcast
Listen To Our World Class Management Team Discuss The Latest Topics In Mental Well Being.